Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
This Biotech Stock Has 47% Upside, According to 1 Wall Street Analyst
06:14am, Friday, 23'rd Feb 2024
Iovance Biotherapeutics is now launching its first cell therapy drug. That's prompting financial analysts to adjust their price targets.
2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value
02:59am, Friday, 23'rd Feb 2024
Analysts are bullish, on average, regarding both Ginkgo Bioworks and Iovance Biotherapeutics. Ginkgo Bioworks' cost-cutting and manufacturing scaling capabilities are being put to the test.
SAN CARLOS, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf
Iovance Biotherapeutics Stock Rockets 41% Higher. Here's Why.
12:52pm, Tuesday, 20'th Feb 2024
Shares of the biotechnology company are on pace for their best day since June 2016.
Iovance Stock Eyes Best Day Since 2020 After FDA Nod
10:26am, Tuesday, 20'th Feb 2024
Iovance Biotherapeutics Inc (NASDAQ:IOVA) stock is up 39.5% at $12.76 at last check, after the company received accelerated approval from the Food and Drug Administration (FDA) for its cell ther
Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma
07:30am, Tuesday, 20'th Feb 2024
Iovance Biotherapeutics' stock has increased over 50% since September, following positive news about its TIL therapy for advanced melanoma. The FDA has granted approval for Iovance's TIL therapy, name
Iovance (IOVA) Stock Rises on FDA Nod for Melanoma Drug Amtagvi
09:41am, Monday, 19'th Feb 2024
The FDA grants accelerated approval to Iovance's (IOVA) Amtagvi (lifileucel) for treating advanced melanoma after anti-PD-1 and targeted therapy. Stock rises.
Iovance (IOVA) stock price could rocket higher ahead of earnings
11:32pm, Saturday, 17'th Feb 2024
Iovance Biotherapeutics (NASDAQ: IOVA) stock price has rebounded this year and is hovering at its highest point since October 2022. It has risen by over 120% as investors focus on the upcoming earning
US FDA grants accelerated approval for Iovance's skin cancer cell therapy
04:07pm, Friday, 16'th Feb 2024
Iovance Biotherapeutics said on Friday the U.S. health regulator had granted accelerated approval for its cell therapy for adult patients with advanced melanoma, the first such treatment to be approve
Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024
03:38pm, Friday, 16'th Feb 2024
SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf
3 Opportunities for Iovance Biotherapeutics Stock, and 1 Risk
07:14am, Monday, 12'th Feb 2024
Iovance Biotherapeutics could commercialize its lead program soon. However, a regulatory inquiry regarding a different program is a major risk.
Is Iovance Biotherapeutics Stock a Buy Now?
07:27am, Thursday, 08'th Feb 2024
Iovance Biotherapeutics could commercialize its first drug soon. It has a number of similar opportunities lined up for the next two years.
Is Iovance Biotherapeutics a Buy Before This Key FDA Decision?
05:10am, Wednesday, 07'th Feb 2024
Iovance expects a regulatory decision on its candidate for advanced melanoma later this month. An approval would be the first for the company's innovative technology -- harnessing the body's own cells
What's Next for Iovance Biotherapeutics Stock?
06:27am, Sunday, 04'th Feb 2024
Iovance Biotherapeutics just reported a significant problem in a clinical trial. It could still get approval for more than one program, and soon.
Iovance: Approval For Historic Solid Tumor Targeting TIL Therapy Likely, Outlook Promising
12:04pm, Sunday, 21'st Jan 2024
Iovance's tumor infiltrating lymphocyte cell therapy candidate, lifileucel, has shown promising results in a study of melanoma patients, with a 31.4% overall response rate. Lifileucel uses a novel mec
